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Congenital Long QT Syndrome
Is One Beta-Blocker Superior to Another?*Arthur A.M. Wilde, MD, PHD,yz Michael J. Ackerman, MD, PHDxT he most common primary inherited ar-rhythmia syndrome is the congenital longQT syndrome (LQTS). Prolonged QT interval
on the electrocardiogram (ECG) is the signature
feature of this disease, which is associated with an
increased propensity to (arrhythmogenic) syncope
and sudden death. The diagnosis is mainly based on
the QT interval corrected for heart rate (QTc), but a
clinical scoring system (the Schwartz score), which
combines molecular genetic testing and several clin-
ical and electrocardiographic parameters, also plays
a role (1). Management of patients with LQTS, whose
risk is predominantly determined by their QTc on the
baseline ECG and by prior expressivity, involves life-
style modiﬁcations (including avoidance of QT-
prolonging drugs) and antiadrenergic therapy, either
by b-blockers (class 1 recommendation in all symp-
tomatic patients and also in asymptomatic patients*Editorials published in the Journal of the American College of Cardiology
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Sudden Cardiac Death Program.with QTc $470 ms) or by left cardiac sympathetic
denervation (class 1 recommendations in “high risk
patients in whom b-blockers are either not effective
in preventing syncope/arrhythmias, not tolerated,
not accepted or contraindicated and/or in whom
implantable cardioverter-deﬁbrillator treatment is
contraindicated or refused”) (1).
The central role of b-blockers in LQTS has been
established since the 1970s (2,3). It is, however,
known that breakthrough cardiac events (BCEs)
occur, particularly in previously symptomatic pa-
tients who are receiving b-blocker treatment (3–8).
Multiple factors are involved in an eventual favorable
response, the most important of which are the dosage
and type of b-blocker. Indeed, differences in the
pharmacodynamics and pharmacokinetics of various
b-blockers (including their lipophilicity) are well
known. Moreover, secondary to the selectivity of
b-blockers for different subtypes of b-adrenergic
receptors, adverse effects are frequent, along with
consequent dose adjustments (9,10). Prospective
studies comparing the efﬁcacy of different b-blockers
have not been performed, so answers to the highly
relevant clinical question, “Is one b-blocker superior
to another?” rely completely on retrospective analysis
in available cohorts.SEE PAGE 1352This issue of the Journal contains the largest
analysis of this type published so far. It compares the
relative efﬁcacies of the most commonly prescribed
b-blockers (nadolol, propranolol, atenolol, and
metoprolol) in 1,530 patients from the LQTS Registry
based in Rochester, New York (11). In the overall
cohort, all b-blockers seem equally effective in
reducing the risk of a ﬁrst cardiac event. In the sub-
cohort of patients with LQTS1 (n ¼ 379), no b-blocker
was superior, whereas in LQTS2 (n ¼ 406), nadolol
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1360was slightly more effective than other b-blockers. In
patients with at least one BCE while taking
b-blockers, propranolol appears to be the least effec-
tive drug (11).
These data are in agreement with our earlier
retrospective analysis in 207 patients with LQTS1 and
176 patients with LQTS2 that showed equal prophy-
lactic efﬁcacy of the 4 b-blockers in asymptomatic
patients and high efﬁcacy of nadolol in both LQT1 and
LQT2 in patients with and without symptoms (8).
However, in the Registry’s symptomatic group,
metoprolol and atenolol are superior to propranolol
(11), whereas in our previous study, propranolol was
superior (8).
That propranolol is the least effective b-blocker in
symptomatic patients in the present study is unex-
pected. In addition to its b-blocker activity, propran-
olol also reduces the QTc, thereby providing another
risk-reducing mechanism of action (8). The authors’
argument that “this (i.e., QTc shortening) has not
been our experience with b-blockers in general (11)”
is not surprising because in the 2000 study (3), all
b-blockers were lumped together; however, not all
b-blockers (by virtue of the presence or absence
of late sodium current blocking efﬁcacy) would be
expected to shorten the QTc (12).
Given the potential impact of therapeutic switches
on the basis of either study, it is critically important
to attempt to understand the cause or causes of these
discrepancies. First, the two studies did not deﬁne
the symptomatic group in the same way. In our pre-
vious study (i.e., the Chockalingam study), the
symptomatic patient group was deﬁned as symp-
tomatic before b-blocker therapy. In this group, the
ﬁrst event that occurred during b-blocker therapy is
counted. In contrast, in the present (Rochester, New
York) study, the event rate is studied in individuals
who already experienced 1 cardiac event while taking
b-blocker therapy (i.e., 1 BCE) and, thus, second and
subsequent events are counted. This latter group is
probably more seriously affected. From Figure 1 in
their article (11), it can be concluded that almost 50%
of BCEs occur within the ﬁrst 6 months after therapy
initiation. In this respect, in contrast to the Chock-
alingam study, the Rochester, New York database
included patients who were diagnosed before 1 year
of age. It is very likely that this cohort, generally
accepted to be at a very high risk (13), is started most
frequently on liquid propranolol 3 to 4 times a day
(14). Indeed, in this cohort (as well as in our study),
the age at which propranolol was started was
younger, and the rapid recurrence of BCEs in almost
half of the propranolol-treated patients with BCEs in
the current study may reﬂect the impact of thissubcohort, in which virtually all therapy fails (in
terms of BCEs) (13). After the ﬁrst 6 months, the
curves no longer deviate. An additional argument for
differences in the groups is the mean age of 24  10
years in the metoprolol subgroup (11), which virtually
excludes the presence of very young children.
Furthermore, in the current study, the comparable
mean QTc values in all groups does not preclude po-
tential differences in the numbers of other high-risk
(with very long QTc) patients included in the 4 sub-
groups. An increased number of such patients in the
propranolol-treated group could easily contribute to a
higher event rate. The lack of these data, critical for
the correct interpretation of the study, is not
compensated for by the current paper’s complex
statistical analysis.
In both studies (8,11), no corrections were made for
including multiple members from single families.
Pharmacokinetic properties of various b-blockers
also rely, in part, on genetic factors (e.g., related to
metabolism), and within given families, these factors
could determine whether b-blocker therapy has
favorable or detrimental effects. Overrepresentation
of such families in either group could skew the results.
In conclusion, the data from both registries clearly
underline the well-known beneﬁcial effect of
b-blocker therapy in LQTS. There is agreement that
nadolol, unfortunately not available in every country
(including the Netherlands), is probably one of the
more effective drugs for this condition. The role
of propranolol, the most widely prescribed drug
(3,11), is now disputed, particularly in symptomatic
patients. At present, retrospective analysis is the
only tool available to address the issue of whether
the b-blocker propranolol should now be deemed
inferior to the b1-selective b-blockers metoprolol
and atenolol.
Great caution must be exercised before rendering
such a conclusion and, as a result, choosing to switch
a patient’s LQTS treatment program from propranolol
to metoprolol or atenolol. These retrospective studies
have inherent limitations (e.g., lack of randomiza-
tion; reliability of the data, potentially even more so if
the physicians in charge of the registry do not see all
the patients themselves; compliance). Furthermore,
we are not aware of a single center (among the largest
LQTS centers throughout the world) directly man-
aging the care of hundreds of patients with LQTS in
which atenolol or metoprolol is the b-blocker of
choice. Instead, virtually every LQTS specialty center
has arrived at an experiential preference for nadolol
or propranolol.
Because both of us have real-world experience
with lethal or near-lethal events after switching
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1361patients from propranolol to atenolol or metoprolol,
it will not be easy to accept the apparent superiority
of the latter drugs over propranolol, as suggested
by the present study. Although we and other in-
vestigators advocate propranolol (and nadolol) over
metoprolol and atenolol (15), solid, irrefutable data
are lacking. Accordingly, we should realize that in-
dividual experience should not prevail over sound
scientiﬁc data.
Hence, the current analysis is of signiﬁcant
importance and should motivate each of us to
compare and extend our data in further detail and try
to discover the b-blocker truth for our patients.
However, it does not seem that the truth will emerge
from a randomized prospective trial. Given theoverall low event rate during b-blocker therapy, to
enroll the huge number of patients necessary, such a
trial would have to be conducted on a worldwide
scale. Moreover, strongly held experiential views may
preclude the participation of some of the largest LQTS
centers that, in the name of “the best interest of the
patient is the only interest to be considered,” may
ﬁnd it difﬁcult to have their patients randomized to
either atenolol or metoprolol.
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